ANN ARBOR, MI / ACCESSWIRE / April 9, 2018 / ENDRA Life Sciences Inc.
("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has been invited to demonstrate its Nexus-128+
preclinical research instrument at the AACR Annual Meeting 2018 being held on April 14-18,
2018 at McCormick Place in Chicago.
ENDRA will showcase its latest photoacoustic computed tomography system, the Nexus 128+, with proprietary 3D imaging technology
in Booth #3446. For a full list of exhibitors, click here.
The Nexus 128 has become a valuable research tool for studying in vivo mouse models of oncologic disease. It combines the most
compelling features of optical imaging and ultrasound to form images with both high optical contrast and high ultrasound resolution
at depth. Various endogenous and exogenous absorbers can serve as photoacoustic contrast agents, which enables the visualization
and quantification of tumor vasculature, volume, tumor heterogeneity, oxygen saturation, hemoglobin concentration, as well as
tumor-targeting molecular probes and putative therapeutic agents.
The Nexus 128+ is equipped with a unique rotating hemispherical array of ultrasound transducers which enables it to acquire
complete 3D volumetric image sets in as little as three seconds. As such, The Nexus 128+ is particularly well suited for studying
the uptake/perfusion of exogenous, tumor-targeting compounds over time, with exceptional spatial and temporal resolution.
"ENDRA's development of preclinical photoacoustic CT scanners used by global research scientists underscores our commitment to
commercializing leading edge tools, and our plan to bring to market a disruptive technology for the clinical market in 2018," said
Francois Michelon, ENDRA's CEO.
"By leveraging our experience with Nexus 128+ technology, ENDRA is developing a more powerful Thermo-Acoustic Enhanced
UltraSound, TAEUS™, for clinical use. Substituting radio frequencies for the near-infrared light of Nexus 128, we've created a
system that can overlay new information on conventional ultrasound - showing tissue temperature, composition, vasculature and
perfusion in real time," concluded Michelon.
About American Association for Cancer Research
The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative
cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs
and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide
training opportunities for the next generation of cancer researchers, and increase public understanding of cancer. For more
information, click here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA's Photo-Acoustic
Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models with high image
quality and volume scanning speed. ENDRA's next generation Thermo-Acoustic Enhanced UltraSound ("TAEUS") will enable clinicians to
visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI - at a fraction of the
cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early
detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally. ENDRA's goal is to
bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has
based any forward-looking statements included in this release on its current expectations, the information on which such
expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual
results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of
Operations sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), which can
be found on the SEC's website at www.sec.gov. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us
SOURCE: ENDRA Life Sciences Inc.
